Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation–positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses. METHODS: Multiple serial tumor and liqui...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JCO Precis Oncol
Главные авторы: Piotrowska, Zofia, Hazar-Rethinam, Mehlika, Rizzo, Coleen, Nadres, Brandon, Van Seventer, Emily E., Shahzade, Heather A., Lennes, Inga T., Iafrate, Anthony J., Dias-Santagata, Dora, Leshchiner, Ignaty, Jessop, Nicholas A., Hu, Haichuan, Digumarthy, Subba R., Nagy, Rebecca J., Lanman, Richard B., Moody, Susan, Niederst, Matthew J., Engelman, Jeffrey A., Hata, Aaron N., Corcoran, Ryan B., Sequist, Lecia V.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2018
Предметы:
Original Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097183/
https://ncbi.nlm.nih.gov/pubmed/30123863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00263
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы